|
Market Closed -
Nasdaq Stockholm
01:00:00 14/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.8480 SEK | +36.77% |
|
-58.63% | -56.95% |
| 11-13 | Irlab narrows operating loss | FW |
| 11-13 | IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 126.1 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | -24.63% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 126.1 | 126.1 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | -24.63% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 1.25x | 0.88x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.25x | 0.88x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -4.44x | 3.27x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -4.02x | 3.64x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.0000 | 38.3000 | 7.5000 | 10.7500 | 1.9700 | 0.8480 | 0.8480 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 23/2/22 | 23/2/23 | 7/2/24 | 12/2/25 | 25/2/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 12.52M | |
| 42.25x | 14.3x | 30.31x | 0.47% | 1,286B | |
| 41.82x | 7.01x | 19.73x | 1.87% | 688B | |
| 37.62x | 8.63x | 17.81x | 2.34% | 521B | |
| 21.75x | 5.27x | 13.2x | 2.48% | 386B | |
| 104.88x | 5.98x | 25.49x | 2.3% | 364B | |
| 24x | 5.82x | 14.17x | 2.73% | 302B | |
| 24.25x | 4.85x | 13.63x | 1.8% | 287B | |
| 24.04x | 7.38x | 13.56x | 2.17% | 252B | |
| -39.49x | 7.32x | 46.07x | 1.96% | 208B | |
| Average | 31.24x | 7.40x | 21.55x | 2.01% | 429B | |
| Weighted average by Cap. | 37.57x | 8.95x | 22.68x | 1.68% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
